Baseline Characteristics of the Subjects

Slides:

Advertisements

Similar presentations

Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:

Advertisements

Rational, Trial Design, and Results of the ADAGIO Delayed Start Trial C. Warren Olanow, MD, FRCPC Henry P. and Georgette Goldschmidt Professor Chairman.

Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:

Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.

Zacho J, et al. N Engl J Med 2008;359: Risk of Ischemic Heart Disease as a Function of Plasma Levels of C-Reactive Protein (CRP) in the General.

Alzheimer’s Disease  Goals  To understand what dementia is  To explore causes, risk factors, symptoms, and treatments of Alzheimer’s Disease  To better.

Functional capacity. Total Score: 0-12 It should be calculated by adding the Score in each one of the three parts of the test (Balance, Gait and Chair.

MRI as a Potential Surrogate Marker in the ADCS MCI Trial

Demographic Characteristics of the Study Population - Part I Jenny N.Poynter et al N Engl J Med 2005;352:

Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

Canadian Study of Health and Aging The Prevalence of Dementia 1991 Baseline Study.

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.

Process of study selection F. Sofi, et al. BMJ 2008 Sep 11;337:a1344.

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Christopher P. Cannon, M. D. , Eugene Braunwald, M. D. , Carolyn H

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial Robert S. Bresalier, M.D., Robert S. Sandler, M.D., Hui Quan,

Baseline Characteristics of the Patients Part I

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

by Edward J. Goetzl, Adam Boxer, Janice B. Schwartz, Erin L

Characteristics of the Folic Acid and Placebo Groups at the Start of the Study J. Durga et al. Arch Intern Med. 2005;165:

TNT: Baseline and final LDL cholesterol levels

Baseline characteristics of patients

TNT Study: Baseline Characteristics of the Patients

Trial profile John A Dormandy et al. Lancet 2005;366:

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Fellström BC, et al. N Engl J Med 2009;360:1455-7

A: Kaplan-Meier estimate of time to first LLA

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

(p for noninferiority < 0.001)

Predictors of disease progression in patients with CKD

Cystatin C levels and risk of death from all causes

Svend A. Mortensen et al. JCHF 2014;2:

Enrollment and Outcomes

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Characteristics of Study Subjects and Events, According to the Quintile of Exposure to Fine Particulate Matter (PM2.5)* - Part I Kristin A. Miller et al.

Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:

A.V. Khera et al. N Engl J Med 2011;364:127-35

Baseline Characteristics of the Study Participants

Baseline Characteristics, Blood Pressures, and Laboratory Values

Baseline Characteristics

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Collet JP, et al. Lancet 2009;373:309-17

Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:

Characteristics of Participants in the Nurses Health Study According to Alcohol Intake Meir J.Stampfer et al N Engl J Med 2005;352:

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development.

Baseline Characteristics of the Patients – Part I

RECORD Study: Enrollment and Outcomes

Kaplan-Meier Curves for the Percentages of Subjects with Microalbuminuria during Treatment with Trandolapril plus Verapamil or Placebo Piero Ruggenenti.

Baseline Characteristics of the Patients - Part I

A Single Participant Exposed Twice to an Inflammatory Stimulus

Cardiovascular risk in chronic kidney disease

Comparison of Baseline Characteristics by Primary End Point

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Flow of study participants

Representative Light Micrographs of Kidney Sections Illustrating the Histologic Scoring Criteria Giuseppe Remuzzi, et al, N Engl J Med 2006;3354:

Frankel DS, et al. J Am Coll Cardiol. 2009;53:754-62

Increase of physical activity over time associated with lower HF risk

Kaplan-Meier estimates of event-free survival in children with non-Hodgkin lymphoma per health-insurance (NHIF) status at diagnosis (P=0.003). Kaplan-Meier.

Kaplan-Meier estimates of event-free survival in children with non-Hodgkin lymphoma (n=63). Kaplan-Meier estimates of event-free survival in children with.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Kaplan-Meier survival (renal event-free) curves during follow-up by tertiles of plasma copeptin. Kaplan-Meier survival (renal event-free) curves during.

Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.

(A) Kaplan-Meier estimates of MACCE in patients with a non-culprit MaxLCBI4mm ≥400 and MaxLCBI4mm

Box plot showing the distribution of the TYM-MCI score for patients with SMC and aMCI/AD. aMCI/AD, amnestic mild cognitive impairment or Alzheimer’s disease;

Presentation transcript:

Baseline Characteristics of the Subjects Ronald C. Petersen et al N Engl J Med 2005;352:2379-88

Kaplan - Meier Estimates of the Rate of Progression from Mild Cognitive Impairment to Alzheimer ’s Disease (AD) Ronald C. Petersen et al N Engl J Med 2005;352:2379-88

Changes from Baseline in Cognitive and Functional Measures Part 1 Ronald C. Petersen et al N Engl J Med 2005;352:2379-88

Changes from Baseline in Cognitive and Functional Measures Part 2 Ronald C. Petersen et al N Engl J Med 2005;352:2379-88

Hazard Ratios for the Risk of Progression to Alzheimer ’s Disease in the Donepezil and Vitamin E Groups as Compared with the Placebo Group Ronald C. Petersen et al N Engl J Med 2005;352:2379-88

Adverse Events Ronald C. Petersen et al N Engl J Med 2005;352:2379-88